An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 Years of Age With Epilepsy
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 24 May 2023 Status changed from active, no longer recruiting to completed.
- 23 Feb 2023 This trial has been completed in Latvia, according to European Clinical Trials Database record.
- 02 Sep 2022 Planned End Date changed from 29 Jun 2023 to 25 May 2023.